However, one of the key strengths of this study is that all patients who were diagnosed with pT1a-b pN0 (including pTmic) HER2-positive breast cancer in our center were evaluated, and there was no selection bias or loss to follow-up. The gene discussed is ERBB2; the disease is breast cancer.